In human trials, cetilistat was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools, [[fecal incontinence]], frequent bowel movements, and [[flatulence]].<ref>{{cite journal | pmid = 16953261 | year = 2007 | last1 = Kopelman | first1 = P | last2 = Bryson | first2 = A | last3 = Hickling | first3 = R | last4 = Rissanen | first4 = A | last5 = Rossner | first5 = S | last6 = Toubro | first6 = S | last7 = Valensi | first7 = P | title = Cetilistat (ATL-962), a novel lipase inhibitor: A 12-week randomized, placebo-controlled study of weight reduction in obese patients | volume = 31 | issue = 3 | pages = 494–9 | doi = 10.1038/sj.ijo.0803446 | journal = International journal of obesity (2005)}}</ref><ref>{{cite journal | pmid = 18393108 | year = 2008 | last1 = Padwal | first1 = R | title = Cetilistat, a new lipase inhibitor for the treatment of obesity | volume = 9 | issue = 4 | pages = 414–21 | journal = Current opinion in investigational drugs (London, England : 2000)}}</ref> It is likely that the same precautions would apply in that absorption of [[fat soluble vitamins|fat-soluble vitamins]] and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.
